Genomic characterization of intrinsic and acquired resistance to cetuximab in colorectal cancer patients

Anti-EGFR antibodies are effective in therapies for late-stage colorectal cancer (CRC); however, many tumours are unresponsive or develop resistance. We performed genomic analysis of intrinsic and acquired resistance to anti-EGFR therapy in prospectively collected tumour samples from 25 CRC patients...

Descripción completa

Detalles Bibliográficos
Autores principales: Bray, Steven M., Lee, Jeeyun, Kim, Seung Tae, Hur, Joon Young, Ebert, Philip J., Calley, John N., Wulur, Isabella H., Gopalappa, Thejaswini, Wong, Swee Seong, Qian, Hui-Rong, Ting, Jason C., Liu, Jiangang, Willard, Melinda D., Novosiadly, Ruslan D., Park, Young Suk, Park, Joon Oh, Lim, Ho Yeong, Kang, Won Ki, Aggarwal, Amit, Kim, Hee Cheol, Reinhard, Christoph
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6814827/
https://www.ncbi.nlm.nih.gov/pubmed/31653970
http://dx.doi.org/10.1038/s41598-019-51981-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6814827/
https://www.ncbi.nlm.nih.gov/pubmed/31653970
http://dx.doi.org/10.1038/s41598-019-51981-5

Ejemplares similares